A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Ischaemic Stroke.

Trial Profile

A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Ischaemic Stroke.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Refanezumab (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 25 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Additional trial location [Germany] identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top